Top

Diagnostic Pathology

Published in:

Open Access 01-12-2014 | Research

Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis

Authors: Weifan Jiang, Guang Sun, Jianhua Xiong, Xiaoqing Xi, Zimin Shi

Published in: Diagnostic Pathology | Issue 1/2014

Abstract

Background

The Cytochrome P450 1B1 (CYP1B1) is a key P450 enzyme involved in the metabolism of exogenous and endogenous substrates. Previous studies have reported the existence of CYP1B1 L432V missense polymorphism in prostate, bladder and renal cancers. However, the effects of this polymorphism on the risk of these cancers remain conflicting. Therefore, we performed a meta-analysis to assess the association between L432V polymorphism and the susceptibility of urinary cancers.

Methods

We searched the PubMed database without limits on language for studies exploring the relationship of CYP1B1 L432V polymorphism and urinary cancers. Article search was supplemented by screening the references of retrieved studies manually. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of these associations. Simultaneously, publication bias was estimated by funnel plot and Begg’s test with Stata 11 software.

Results

We observed a significant association between CYP1B1 L432V polymorphism and urinary cancers. The overall OR (95% CI) of CC versus CG was 0.937 (0.881-0.996), the overall OR (95% CI) of CC versus CG + GG was 0.942 (0.890-0.997). Furthermore, we identified reduced risk for CC versus other phenotypes in both prostate and overall urinary cancers, when studies were limited to Caucasian or Asian patients.

Conclusions

This meta-analysis suggests that the CYP1B1 L432V polymorphism is associated with urinary cancer risk.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3108829721231527

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.PubMedCrossRef

Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 2014, 64: 9-29. 10.3322/caac.21208.PubMedCrossRef

Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu YP, Kogevinas M, Wang Z, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Gapstur SM, Thun M, et al.: Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013, 73: 2211-2220. 10.1158/0008-5472.CAN-12-2388.PubMedPubMedCentralCrossRef

Joshi AD, Corral R, Catsburg C, Lewinger JP, Koo J, John EM, Ingles SA, Stern MC: Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case–control study. Carcinogenesis. 2012, 33: 2108-2118. 10.1093/carcin/bgs242.PubMedPubMedCentralCrossRef

Agundez JA: Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004, 5: 211-224. 10.2174/1389200043335621.PubMedCrossRef

Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR: 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A. 1996, 93: 9776-9781. 10.1073/pnas.93.18.9776.PubMedPubMedCentralCrossRef

Sutter CH, Qian Z, Hong YP, Mammen JS, Strickland PT, Sutter TR: Genotyping human cytochrome: P450 1B1 variants. Methods Enzymol. 2002, 357: 53-58.PubMedCrossRef

Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF: Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 2000, 60: 3440-3444.PubMed

Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T: Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics. 2000, 10: 343-353. 10.1097/00008571-200006000-00008.PubMedCrossRef

10.

Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K: Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999, 20: 1607-1613. 10.1093/carcin/20.8.1607.PubMedCrossRef

11.

Dou K, Xu Q, Han X: The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol. 2013, 8: 112-10.1186/1746-1596-8-112.PubMedPubMedCentralCrossRef

12.

Xu W, Zhang H, Wang F, Wang H: Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer. Diagn Pathol. 2013, 8: 95-10.1186/1746-1596-8-95.PubMedPubMedCentralCrossRef

13.

Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA, Stanford JL: Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate. 2013, 73: 1-10. 10.1002/pros.22534.PubMedPubMedCentralCrossRef

14.

Catsburg C, Joshi AD, Corral R, Lewinger JP, Koo J, John EM, Ingles SA, Stern MC: Polymorphisms in carcinogen metabolism enzymes, fish intake, and risk of prostate cancer. Carcinogenesis. 2012, 33: 1352-1359. 10.1093/carcin/bgs175.PubMedPubMedCentralCrossRef

15.

Beuten J, Gelfond JA, Byrne JJ, Balic I, Crandall AC, Johnson-Pais TL, Thompson IM, Price DK, Leach RJ: CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis. 2008, 29: 1751-1757. 10.1093/carcin/bgm300.PubMedPubMedCentralCrossRef

16.

Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, Hayes RB: Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16: 165-168. 10.1158/1055-9965.EPI-06-0689.PubMedCrossRef

17.

Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G: Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol. 2007, 25: 3596-3602. 10.1200/JCO.2007.11.0908.PubMedCrossRef

18.

Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, Mohan H: CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 2006, 25: 287-294. 10.1089/dna.2006.25.287.PubMedCrossRef

19.

Cicek MS, Liu X, Casey G, Witte JS: Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2173-2177. 10.1158/1055-9965.EPI-05-0215.PubMedCrossRef

20.

Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, Ichikawa T, Tsukino H, Qiu D, Katoh T, Sugimura Y, Yatani R, Shiraishi T, Watanabe M: Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 2004, 24: 2431-2437.PubMed

21.

Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J: Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer. 2003, 89: 1524-1529. 10.1038/sj.bjc.6601288.PubMedPubMedCentralCrossRef

22.

Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R: Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun. 2002, 296: 820-826. 10.1016/S0006-291X(02)02004-1.PubMedCrossRef

23.

Berber U, Yilmaz I, Yilmaz O, Haholu A, Kucukodaci Z, Ates F, Demirel D: CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population. Asian Pac J Cancer Prev. 2013, 14: 3925-3929. 10.7314/APJCP.2013.14.6.3925.PubMedCrossRef

24.

Salinas-Sanchez AS, Donate-Moreno MJ, Lopez-Garrido MP, Gimenez-Bachs JM, Escribano J: Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility. J Urol. 2012, 187: 700-706. 10.1016/j.juro.2011.10.063.PubMedCrossRef

25.

Fontana L, Delort L, Joumard L, Rabiau N, Bosviel R, Satih S, Guy L, Boiteux JP, Bignon YJ, Chamoux A, Bernard-Gallon DJ: Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res. 2009, 29: 1631-1635.PubMed

26.

Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Lan Q, Tardón A, Serra C, Carrato A, García-Closas R, Castaño-Vinyals G, Rothman N: Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 2008, 29: 1955-1962. 10.1093/carcin/bgn163.PubMedPubMedCentralCrossRef

27.

Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, Scotto di Carlo A, Porru S: GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004, 110: 598-604. 10.1002/ijc.20157.PubMedCrossRef

28.

Salinas-Sanchez AS, Sanchez-Sanchez F, Donate-Moreno MJ, Rubio-del-Campo A, Serrano-Oviedo L, Gimenez-Bachs JM, Martinez-Sanchiz C, Segura-Martin M, Escribano J: GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer. Urol Oncol. 2012, 30: 864-870. 10.1016/j.urolonc.2010.10.001.PubMedCrossRef

29.

Sasaki M, Tanaka Y, Okino ST, Nomoto M, Yonezawa S, Nakagawa M, Fujimoto S, Sakuragi N, Dahiya R: Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin Cancer Res. 2004, 10: 2015-2019. 10.1158/1078-0432.CCR-03-0166.PubMedCrossRef

30.

DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.PubMedCrossRef

31.

Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22: 719-748.PubMed

32.

Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.PubMedPubMedCentralCrossRef

33.

Carnell DM, Smith RE, Daley FM, Barber PR, Hoskin PJ, Wilson GD, Murray GI, Everett SA: Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys. 2004, 58: 500-509. 10.1016/j.ijrobp.2003.09.064.PubMedCrossRef

34.

Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM: Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica. 2001, 31: 163-176. 10.1080/00498250110043490.PubMedCrossRef

Title: Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis
Authors: Weifan Jiang
Guang Sun
Jianhua Xiong
Xiaoqing Xi
Zimin Shi
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/1746-1596-9-113

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis

Abstract

Background

Methods

Results

Conclusions

Virtual Slides

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Virtual Slides

Please log in to get access to this content

Other articles of this Issue 1/2014

Students' performance during practical examination on whole slide images using view path tracking

Tumour-to-tumour metastasis: male breast carcinoma metastasis arising in an extrapleural solitary fibrous tumour - a case report

Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia

Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials

Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma

Primary spleen extranodal NK/T cell lymphoma, nasal type, with bone marrow involvement and CD30 positive expression: a case report and literature review